查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1634215

全球近距離治療設備市場 - 2025 - 2033

Global Brachytherapy Devices Market - 2025 - 2033
出版日期: | 出版商: DataM Intelligence | 英文 169 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球近距離治療設備市場規模達到10.241億美元，預計2033年將達到19.027億美元，2025-2033年預測期間複合年成長率為7.2%。

近距離放射治療設備是指用於近距離放射治療的專用醫療設備，近距離放射治療是一種內部放射治療，其中放射源直接放置在腫瘤內部或非常靠近腫瘤。這些設備為腫瘤提供高劑量的輻射，同時最大限度地減少對周圍健康組織的照射，使其成為一種有針對性的有效治療方法，特別是對於局部癌症。近距離放射治療為各種類型的癌症提供了有效且有針對性的治療方法。精確性、副作用減少和治療時間更短使其成為局部癌症患者的寶貴選擇。

在癌症盛行率不斷上升、技術進步以及對微創治療的日益偏好等因素的推動下，全球近距離治療設備市場正在經歷顯著成長。例如，根據《國際放射腫瘤學、生物學、物理學雜誌》進行的研究，8500 名女性中，36% 只接受了 EBRT，64% 則在 EBRT 的基礎上接受了近距離放射治療。在經歷了 2003-2004 年的急劇下降（2003 年最低為 44%）之後，近距離放射治療的使用率穩步上升，特別是從 2018 年到 2020 年（76%）。

市場動態：

驅動程式和限制

癌症盛行率上升

癌症盛行率的上升極大地推動了近距離治療設備市場的成長，預計將在預測期內推動該市場的發展。近距離放射治療對於攝護腺癌、乳癌、子宮頸癌和皮膚癌等局部癌症特別有效。該方法直接向腫瘤提供高劑量的輻射，最大限度地減少對周圍健康組織的損害，這對於患有這些不斷增加的癌症病例的患者至關重要。例如，根據美國國立衛生研究院的數據，全球死亡的主要原因之一是癌症。全球範圍內，2022 年將新增約 2,000 萬例癌症病例。

近距離放射治療被認為是局部前列腺癌的首選治療方法，尤其是早期腫瘤。它能夠提供高輻射劑量，同時對膀胱和直腸等附近器官的損害最小，使其成為針對不斷成長的患者群體的高效治療方法。例如，根據美國癌症協會的估計，2024年美國將新增約299,010例前列腺癌病例。

近距離放射治療相關的高成本

近距離放射治療的高成本是阻礙近距離放射治療設備市場成長的重要因素。該成本的幾個方面，包括設備的初始投資、持續維護和放射性材料的成本，都對廣泛採用構成了障礙，特別是在醫療保健預算有限的地區。例如，根據 HOSPIDIO 的說法，印度的近距離放射治療費用從 2000 美元到 4500 美元不等，相當於大約 160000 到 370000 印度盧比。

購買後裝機、施藥器和治療計劃系統等近距離治療設備的成本可能從數十萬到數百萬美元不等。例如，現代近距離放射治療程序中常用的高劑量率 (HDR) 後裝置的成本可能很高，具體取決於型號和技術。

例如，根據美國國立衛生研究院 (NIH) 的數據，2020 年 HDR 後加載器的平均成本將在 200,000 美元至 350,000 美元之間，每年經常性的服務和源交換費用將遠遠超過 20,000 美元。

目錄

第1章：市場介紹和範圍

  • 報告的目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按劑量類型分類的片段
  • 按產品類型分類的片段
  • 按技術類型分類的片段
  • 按應用程式片段
  • 最終使用者的片段
  • 按地區分類的片段

第 3 章：動力學

  • 影響因素
    • 促進要素
      • 癌症盛行率上升
    • 限制
      • 近距離放射治療的高成本
    • 機會
    • 影響分析

第 4 章：策略洞察與產業展望

  • 市場領導者和先驅
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的知名領導者
    • 擁有成熟產品的市場領導者
  • 新興新創企業和關鍵創新者
  • CXO 觀點
  • 最新進展和突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：近距離放射治療設備市場（按劑量類型）

  • 高劑量率 (HDR) 近距離放射治療
  • 低劑量率 (LDR) 近距離放射治療

第 6 章：近距離放射治療設備市場（依產品類型）

  • 種子
  • 近距離放射治療槍
  • 近距離治療後裝機
  • 電子近距離放射治療

第 7 章：近距離放射治療設備市場（依技術類型）

  • 超音波導引近距離放射治療
  • 磁振造影 (MRI) 引導近距離放射治療
  • 電腦斷層掃描 (CT) 導引近距離放射治療
  • 正子斷層掃描 (PET) 導引近距離放射治療
  • 其他

第 8 章：近距離放射治療設備市場（按應用）

  • 攝護腺癌
  • 皮膚癌
  • 婦科癌症
  • 乳癌
  • 子宮頸癌
  • 其他

第 9 章：近距離放射治療設備市場（依最終用戶）

  • 醫院
  • 診斷中心
  • 放射治療中心
  • 門診手術中心
  • 其他

第 10 章：近距離放射治療設備市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的主要發展
  • 公司基準化分析

第 12 章：公司簡介

  • Elekta AB
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
    • SWOT分析
  • Varian Medical Systems, Inc.
  • Eckert & Ziegler
  • Theragenics Corporation
  • Becton, Dickinson, and Company
  • BEBIG Medical
  • Sun Nuclear Corporation
  • CIVCO Medical Solutions

第 13 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 14 章：附錄

簡介目錄
Product Code: MD7683

The global brachytherapy devices market reached US$ 1,024.1 million in 2024 and is expected to reach US$ 1,902.7 million by 2033, growing at a CAGR of 7.2% during the forecast period 2025-2033.

Brachytherapy devices refer to specialized medical devices used in brachytherapy, a form of internal radiation therapy where radioactive sources are placed directly inside or very close to a tumor. The devices deliver a high dose of radiation to the tumor while minimizing exposure to surrounding healthy tissues, making it a targeted and effective treatment, especially for localized cancers. Brachytherapy offering an effective and targeted treatment method for various types of cancer. The precision, reduced side effects and shorter treatment times make it a valuable option for patients with localized cancers.

The global brachytherapy devices market is experiencing significant growth, driven by factors such as the increasing prevalence of cancer, technological advancements and a rising preference for minimally invasive treatments. For instance, according to the study conducted by International Journal of Radiation Oncology, Biology, Physics, of the 8500 women, 36% underwent EBRT alone, and 64% received brachytherapy in addition to EBRT. After a steep fall in 2003-2004 (with the lowest rate of 44% in 2003), the brachytherapy usage rate steadily increased, particularly from 2018 to 2020 (76%).

Market Dynamics: Drivers & Restraints

Rising prevalence of cancer

The rising prevalence of cancer is significantly driving the growth of the brachytherapy devices market and is expected to drive the market over the forecast period. Brachytherapy is particularly effective for localized cancers like prostate, breast, cervical and skin cancers. The method delivers high doses of radiation directly to the tumor, minimizing damage to surrounding healthy tissue, which is crucial for patients suffering from these increasing cancer cases. For instance, according to the National Institute of Health, one of the main causes of mortality in the globe is cancer. Globally, there were about 20 million new cases in 2022. It is anticipated that there will be 29.9 million new cancer cases year by 2040.

Brachytherapy is considered a preferred treatment for localized prostate cancer, particularly in early-stage tumors. Its ability to provide a high radiation dose with minimal damage to nearby organs, such as the bladder and rectum, makes it a highly effective treatment method for this growing patient population. For instance, according to the American Cancer Society's estimates in the United States in 2024, about 299,010 new cases of prostate cancer.

High cost associated with brachytherapy

The high cost associated with brachytherapy is a significant factor that hampers the growth of the brachytherapy devices market. Several aspects of this cost, including the initial investment in equipment, ongoing maintenance and the cost of radioactive materials, present barriers to widespread adoption, particularly in regions with limited healthcare budgets. For instance, according to the HOSPIDIO, brachytherapy cost in India can range from $2000 to $4500, which is equivalent to approximately 1,60,000 to 3,70,000 Indian rupees.

The cost of purchasing brachytherapy equipment such as afterloaders, applicators, and treatment planning systems can range from hundreds of thousands to millions of dollars. For instance, a high-dose rate (HDR) afterloader, which is commonly used in modern brachytherapy procedures, can cost high depending on the model and technology.

For instance, according to the National Institute of Health (NIH), an HDR afterloader will cost between USD 200,000 and USD 350,000 on average in 2020, with recurring yearly servicing and source exchange expenses of well over USD 20,000.

Segment Analysis

The global brachytherapy devices market is segmented based on dosage type, product type, technique type, application, end-user and region.

Dosage Type:

The High-Dose Rate (HDR) brachytherapy segment is expected to dominate the brachytherapy devices market share

High-Dose Rate (HDR) brachytherapy allows for the delivery of a high dose of radiation in a short period, enabling precise targeting of the tumor. This results in better tumor control with minimal damage to surrounding healthy tissue. HDR brachytherapy sessions are typically much shorter than those of Low Dose Rate (LDR), which makes it more convenient for both patients and healthcare providers. HDR treatments can be completed within a few minutes per session, whereas LDR treatments can span several days.

High-Dose Rate (HDR) brachytherapy is widely used in the treatment of localized prostate cancer. In prostate cancer treatment, HDR has shown comparable, if not superior, outcomes to LDR in terms of tumor control, with a shorter treatment duration.

For instance, in July 2024, GE HealthCare's MIM Software introduced MIM Symphony HDR Prostate to support high dose-rate (HDR) brachytherapy. By offering direct tumor visualization from magnetic resonance imaging (MRI) images during live ultrasound operations for HDR prostate treatments, this novel technology seeks to boost clinician confidence and contribute to better patient outcomes. By providing MRI guiding and correcting MRI alignment during HDR prostate treatments, MIM Symphony HDR Prostate distinguishes itself in the industry.

Geographical Analysis

North America is expected to hold a significant position in the brachytherapy devices market share

According to the American Cancer Society, approximately 1.9 million new cancer cases were expected to be diagnosed in the United States in 2023, with prostate, breast, and gynecological cancers being some of the most common. This rising cancer burden creates a growing demand for effective, targeted treatments like brachytherapy.

The U.S. has one of the highest incidences of prostate cancer globally, with an estimated 1 in 8 men being diagnosed. Brachytherapy, particularly HDR brachytherapy, is a leading treatment choice for localized prostate cancer, contributing significantly to the growth of the brachytherapy devices market.

North America has seen significant adoption of high-dose rate (HDR) brachytherapy devices, which offer superior precision and faster treatment times. The use of real-time imaging, automated afterloaders, and improved treatment planning systems are particularly prevalent in this region, enhancing the effectiveness of brachytherapy treatments.

Companies like Varian Medical Systems, Elekta and other emerging players are based in North America and lead the development of next-generation brachytherapy devices. These innovations ensure that North American healthcare providers are equipped with the most advanced technologies available.

Asia-Pacific is growing at the fastest pace in the brachytherapy devices market

The APAC region has seen a significant rise in cancer cases due to factors such as population growth, aging populations, urbanization, and lifestyle changes. According to the International Agency for Research on Cancer (IARC), Asia accounted for 47% of the global cancer burden in 2020. Countries like China, India, and Japan have some of the highest cancer rates globally. This surge in cancer cases is driving demand for effective treatments like brachytherapy.

Governments in APAC countries are increasingly investing in healthcare infrastructure, including cancer treatment facilities. This investment is critical for expanding access to advanced therapies like brachytherapy. For instance, the Indian government's focus on improving healthcare access and cancer treatment capabilities has resulted in greater availability of brachytherapy devices in the country.

As patients in the APAC region increasingly demand minimally invasive treatment options, the adoption of brachytherapy continues to rise. Its ability to deliver targeted radiation with reduced risk of side effects and shorter recovery times makes it an attractive treatment option. For instance, in South Korea, patients are becoming more inclined toward advanced cancer therapies like HDR brachytherapy, which requires fewer hospital visits and allows for faster recovery compared to traditional external beam radiation therapy.

Competitive Landscape

The major global players in the brachytherapy devices market include Elekta AB, Varian Medical Systems, Inc., Eckert & Ziegler, Theragenics Corporation, Becton, Dickinson, and Company, BEBIG Medical, Sun Nuclear Corporation, CIVCO Medical Solutions and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global brachytherapy devices market report delivers a detailed analysis with 72 key tables, more than 77 visually impactful figures, and 169 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Dosage Type
  • 2.4. Snippet by Product Type
  • 2.5. Snippet by Technique Type
  • 2.6. Snippet by Application
  • 2.7. Snippet by End-User
  • 2.8. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Cancer
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Brachytherapy
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Brachytherapy Devices Market, By Dosage Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 5.1.2. Market Attractiveness Index, By Dosage Type
  • 5.2. High-Dose Rate (HDR) Brachytherapy*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Low-Dose Rate (LDR) Brachytherapy

6. Brachytherapy Devices Market, By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Seeds*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Brachytherapy Applicators
  • 6.4. Brachytherapy Afterloaders
  • 6.5. Electronic Brachytherapy

7. Brachytherapy Devices Market, By Technique Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 7.1.2. Market Attractiveness Index, By Technique Type
  • 7.2. Ultrasound-Guided Brachytherapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Magnetic Resonance Imaging (MRI)-Guided Brachytherapy
  • 7.4. Computed Tomography (CT)-Guided Brachytherapy
  • 7.5. Positron Emission Tomography (PET)-Guided Brachytherapy
  • 7.6. Others

8. Brachytherapy Devices Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Prostate Cancer*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Skin Cancer
  • 8.4. Gynecological Cancer
  • 8.5. Breast Cancer
  • 8.6. Cervical Cancer
  • 8.7. Others

9. Brachytherapy Devices Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Radiotherapy Centers
  • 9.5. Ambulatory Surgical Centers
  • 9.6. Others

10. Brachytherapy Devices Market, By Regional Market Analysis and Growth Opportunities

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. U.K.
      • 10.3.8.3. France
      • 10.3.8.4. Spain
      • 10.3.8.5. Italy
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

  • 11.1. Competitive Overview and Key Market Players
  • 11.2. Market Share Analysis and Positioning Matrix
  • 11.3. Strategic Partnerships, Mergers & Acquisitions
  • 11.4. Key Developments in Product Portfolios and Innovations
  • 11.5. Company Benchmarking

12. Company Profiles

  • 12.1. Elekta AB*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
    • 12.1.5. SWOT Analysis
  • 12.2. Varian Medical Systems, Inc.
  • 12.3. Eckert & Ziegler
  • 12.4. Theragenics Corporation
  • 12.5. Becton, Dickinson, and Company
  • 12.6. BEBIG Medical
  • 12.7. Sun Nuclear Corporation
  • 12.8. CIVCO Medical Solutions

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

  • 13.1. Data Collection Methods
  • 13.2. Data Triangulation
  • 13.3. Forecasting Techniques
  • 13.4. Data Verification and Validation

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us